^
    Back
    Association details:
    Biomarker:MYC rearrangement + BCL2 rearrangement
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) +
    Brukinsa (zanubrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    EHA 2021
    Title:

    ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE TREATMENT FOR DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)

    Published date:
    05/12/2021
    Excerpt:
    1 patient (1/10) was diagnosed as double-hit DLBCL and 7 patients (7/10) as double-expression….The ORR was 100.0%, with 9 patients achieved CR (9/10) and 1 patients achieved PR (1/10)….ZR2-CHOP for high-risk DLBCL patients with fair physical condition could achieve high CRR and high proportion of early-stage undetectable ctDNA.
    Secondary therapy:
    R-CHOP